3种抗组胺药治疗慢性荨麻疹的最小成本分析  

Cost-minimization Analysis on 3 Antihistamines for Chronic Urticaria

作　　者：徐欣昌 田晓云 褚福莲 

机构地区：[1]山东枣庄矿业集团中心医院药剂科,枣庄市277011

出　　处：《中国药房》2008年第26期2006-2007,共2页China Pharmacy

摘　　要：目的:评价3种抗组胺药治疗慢性荨麻疹的疗效和经济学效果。方法:99例慢性荨麻疹患者随机分为A、B、C组,分别给予氯马斯汀、西替利嗪、氯雷他定治疗28d,观察疗效及停药7d内的复发率,并运用最小成本分析法进行研究。结果:A、B、C组的有效率分别为96.8%、94.3%、93.8%(P>0.05),停药7d内的复发率分别为41.9%、31.4%、30.3%,药品成本分别为47.35、40.60、73.72元。结论:西替利嗪较经济。OBJECTIVE： To evaluate the therapeutic efficacy and pharmacoeconomic outcome of 3 antihistamines in the treatment of chronic urticaria. METHODS： 99 patients with chronic urticaria were randomly assigned to receive clemastine （Group A）, cetirizine （Group B） or lortatine （Group C） for 28 days. The therapeutic effects and recurrence rate within 7 days after drug withdrawal were observed, and the outcomes were analyzed using cost- minimization analysis. RESULTS： The effective rates in Group A, B, and C were 96.8%, 94.3%, and 93.8 % （P 〉 0.05）, respectively. The recurrence rates within 7 days after discontinuation of the treatment were 41.9%, 31.4%, and 30.3%, respectively. The drug costs were 47.35 yuan, 40.60 yuan and 73.72 yuan, respectively. CONCLUSION： Cetrizine is the most economical therapy for chronic urticaria.

关 键 词：慢性荨麻疹 氯马斯汀 西替利嗪 氯雷他定 最小成本分析 

分 类 号：R956[医药卫生—药学] R986